Enzyme (MLN) Price Prediction

By CMC AI
12 June 2026 10:16PM (UTC+0)
TLDR

Enzyme faces a challenging near-term outlook but holds potential if adoption accelerates.

  1. Exchange Delisting – Binance removed MLN on May 27, 2026, crushing liquidity and investor confidence, a major near-term headwind.

  2. Tokenomics & Usage – Annual minting of 300,600 MLN could outpace fee burns, pressuring price unless vault AUM grows significantly.

  3. Adoption & Partnerships – New products (Onyx, Myso) and alliances with Rayls and CV5 Capital could drive long-term demand if successfully integrated.

Deep Dive

1. Major Exchange Delisting (Bearish Impact)

Overview: Binance, the world's largest exchange, delisted MLN along with four other altcoins on May 27, 2026 (CoinMarketCap). The token had been placed on a "Monitoring Tag" in April, signaling compliance concerns. Such removals drastically reduce liquidity, accessibility, and perceived legitimacy, often leading to sustained selling pressure as seen in MLN's 18% drop post-announcement.

What this means: The loss of a top-tier trading venue severely limits buying interest and increases volatility, creating a persistent overhang on the price. Recovery requires regaining listings on other major exchanges or demonstrating outsized fundamental growth to offset the liquidity crunch.

2. Inflationary Tokenomics vs. Utility Demand (Mixed Impact)

Overview: MLN's value is tied to protocol usage. Users pay fees in MLN (0.25% of linked AUM), which are then burned. However, the protocol mints up to 300,600 new MLN annually for development grants (Enzyme Docs). The documentation notes that "inflation is likely to exceed the amount burnt for many years," creating sell pressure unless vault AUM grows rapidly.

What this means: This structure is bearish if platform growth lags, as new supply dilutes holders. It becomes bullish only if vault adoption accelerates enough for burn rates to surpass inflation, making AUM growth the critical metric to watch for a sustainable price floor.

3. Product Expansion & Institutional Partnerships (Bullish Impact)

Overview: Despite market headwinds, Enzyme is building for the future. It joined Rayls as a launch partner in May 2026 and formed a strategic partnership with CV5 Capital, which will use Enzyme Onyx as its core tech stack for tokenized funds (Enzyme, Binance Square). These moves target the growing institutional tokenized finance market.

What this means: Successful integration and adoption by partners would directly increase fee-generating AUM, boosting MLN's utility demand and burn rate. This is a long-term catalyst that could help the token decouple from its recent exchange-driven decline, but real impact depends on execution and broader market timing.

Conclusion

MLN's path is bifurcated: near-term price action is shackled by the Binance delisting and inflationary tokenomics, while its long-term prospect hinges on converting its institutional partnerships into real, growing usage. For a holder, this implies weathering high volatility with a focus on whether AUM metrics can eventually overcome the token's structural supply pressures.

Can the growth in vault assets under management outpace the annual minting of new MLN tokens?

CMC AI can make mistakes. Not financial advice.